Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

• Главные авторы: Kei Nakashima (Автор), Masayuki Ishida (Автор), Hiroki Matsui (Автор), Chihiro Yoshida (Автор), Tatsuya Nagai (Автор), Minoru Shiraga (Автор), Hiroshi Nakaoka (Автор), Yoshihito Otsuka (Автор), Yu Nakagama (Автор), Natsuko Kaku (Автор), Yuko Nitahara (Автор), Yasutoshi Kido (Автор), Yoshio Hirota (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

This study assessed the immunogenicity and safety of the BNT162b2 mRNA vaccine in lung cancer patients receiving anticancer treatment. We enrolled lung cancer patients receiving anticancer treatment and non-cancer patients; all participants were fully vaccinated with the BNT162b2 vaccine. Blood samp...